RS64942B1 - Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema - Google Patents

Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema

Info

Publication number
RS64942B1
RS64942B1 RS20231190A RSP20231190A RS64942B1 RS 64942 B1 RS64942 B1 RS 64942B1 RS 20231190 A RS20231190 A RS 20231190A RS P20231190 A RSP20231190 A RS P20231190A RS 64942 B1 RS64942 B1 RS 64942B1
Authority
RS
Serbia
Prior art keywords
ethoxy
glp
given
composition according
amino
Prior art date
Application number
RS20231190A
Other languages
English (en)
Serbian (sr)
Inventor
Thomas Vilhelmsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64942(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS64942B1 publication Critical patent/RS64942B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20231190A 2012-03-22 2013-03-15 Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema RS64942B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12160742 2012-03-22
US201361748844P 2013-01-04 2013-01-04
EP13153422 2013-01-31
EP18212576.5A EP3542790B1 (en) 2012-03-22 2013-03-15 Compositions comprising a delivery agent and preparation thereof

Publications (1)

Publication Number Publication Date
RS64942B1 true RS64942B1 (sr) 2024-01-31

Family

ID=49221869

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20190386A RS58636B1 (sr) 2012-03-22 2013-03-15 Kompozicije koje sadrže sredstvo za isporuku i njihova priprema
RS20231190A RS64942B1 (sr) 2012-03-22 2013-03-15 Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20190386A RS58636B1 (sr) 2012-03-22 2013-03-15 Kompozicije koje sadrže sredstvo za isporuku i njihova priprema

Country Status (11)

Country Link
US (1) US10335369B2 (enExample)
EP (3) EP3542790B1 (enExample)
JP (1) JP6356660B2 (enExample)
CN (3) CN111494323B (enExample)
ES (1) ES2965469T3 (enExample)
HR (1) HRP20231613T1 (enExample)
HU (1) HUE064694T2 (enExample)
PL (2) PL3542790T3 (enExample)
RS (2) RS58636B1 (enExample)
SI (1) SI2827845T1 (enExample)
WO (1) WO2013139695A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
DK2827845T3 (en) * 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN111494323B (zh) 2012-03-22 2023-03-28 诺和诺德股份有限公司 包含递送剂的组合物及其制备
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
CN104173313B (zh) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
AU2016206950B2 (en) 2015-01-12 2021-05-06 Enteris Biopharma, Inc. Solid oral dosage forms
WO2018121702A1 (zh) * 2016-12-30 2018-07-05 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
SG11202006595RA (en) * 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020152304A1 (en) * 2019-01-24 2020-07-30 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
CN114222581A (zh) * 2019-08-07 2022-03-22 诺和诺德股份有限公司 包含egf(a)衍生物和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
WO2021043803A1 (en) 2019-09-02 2021-03-11 Novo Nordisk A/S Process for producing a tablet comprising glp-1 peptides
US12364663B2 (en) 2019-09-06 2025-07-22 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US20230165939A1 (en) * 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
EP4185606A1 (en) * 2020-07-22 2023-05-31 Novo Nordisk A/S Glp-1 and gip receptor co-agonists
PE20231841A1 (es) * 2020-07-22 2023-11-21 Novo Nordisk As Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
CA3218339A1 (en) 2021-05-07 2022-11-10 Aktham Aburub Erodible tablet
AU2022312702A1 (en) 2021-07-15 2024-01-18 Novo Nordisk A/S Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
KR20240118786A (ko) * 2021-12-01 2024-08-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
ES2059366T3 (es) 1986-03-12 1994-11-16 American Cyanamid Co Compuestos macrolidos.
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
WO1999043341A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
CA2361716C (en) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CZ20032828A3 (en) 2001-03-27 2004-07-14 Ranbaxy Laboratories Limited A stable pharmaceutical composition of pravastatin
IL158518A0 (en) 2001-05-15 2004-05-12 Warner Lambert Co Compaction process for manufacture of sodium phenytoin dosage form
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20040259952A1 (en) 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
NZ534234A (en) 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
CA2473340C (en) 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
JP2006528982A (ja) 2003-05-14 2006-12-28 エミスフェアー・テクノロジーズ・インク ペプチドｙｙおよびｐｙｙ作用薬の送達用組成物
PT1651248E (pt) 2003-07-11 2009-11-10 Novartis Ag Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
NZ550894A (en) * 2004-05-06 2011-02-25 Emisphere Tech Inc Solid dosage form of wetted heparin
JP4903690B2 (ja) 2004-05-06 2012-03-28 エミスフェアー・テクノロジーズ・インク Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体
US8273794B2 (en) 2004-05-14 2012-09-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005115347A1 (en) 2004-05-31 2005-12-08 Sam-A Pharmaceuticals Co., Ltd. Dispersible tablet comprising beta lactam antibiotics and process for preparing the same
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
EP2289560B1 (en) 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
EP1799711B1 (en) 2004-10-07 2012-06-20 Novo Nordisk A/S Protracted exendin-4 compounds
US8852632B2 (en) 2004-12-03 2014-10-07 Merck Sharp & Dohme Corp. Pharmaceutical formulation containing a release rate controlling composition
EP1843755B1 (en) 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
EP1863449A2 (en) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
BRPI0618723A2 (pt) 2005-11-17 2011-09-06 Novartis Ag composição farmacêutica oral na forma de um comprimido prensado
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
US9364502B2 (en) * 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
CN101506147B (zh) 2006-09-07 2012-03-21 霍夫曼-拉罗奇有限公司 用于制备snac（n-（8-[2-羟基苯甲酰基]-氨基）辛酸钠）的方法
AR062925A1 (es) 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
WO2008070547A1 (en) * 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
ATE507818T1 (de) 2007-03-02 2011-05-15 Novartis Ag Orale verabreichung eines calcitonins
US20110183889A1 (en) 2007-08-29 2011-07-28 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
PL2203181T3 (pl) 2007-10-16 2018-07-31 Biocon Limited Podawana doustnie stała kompozycja farmaceutyczna i jej sposób
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CA2734442C (en) 2008-08-18 2016-08-16 Oramed Ltd Methods and compositions for oral administration of proteins
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CA2784120A1 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
GB2478849A (en) 2010-03-16 2011-09-21 Chiasma Inc Improved pharmecutical compositions and methods of delivery
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
PL3326620T3 (pl) * 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
CN111494323B (zh) 2012-03-22 2023-03-28 诺和诺德股份有限公司 包含递送剂的组合物及其制备
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1

Also Published As

Publication number Publication date
CN111494323B (zh) 2023-03-28
WO2013139695A1 (en) 2013-09-26
CN111494324A (zh) 2020-08-07
EP3542790A1 (en) 2019-09-25
US10335369B2 (en) 2019-07-02
PL2827845T3 (pl) 2019-06-28
EP3542790B1 (en) 2023-09-13
US20150031606A1 (en) 2015-01-29
EP4331667A3 (en) 2024-05-08
JP2015515459A (ja) 2015-05-28
EP2827845A1 (en) 2015-01-28
HRP20231613T1 (hr) 2024-03-15
HUE064694T2 (hu) 2024-04-28
RS58636B1 (sr) 2019-05-31
CN104203221A (zh) 2014-12-10
PL3542790T3 (pl) 2024-02-26
CN111494324B (zh) 2023-05-16
ES2965469T3 (es) 2024-04-15
CN111494323A (zh) 2020-08-07
EP4331667A2 (en) 2024-03-06
SI2827845T1 (sl) 2019-04-30
EP3542790C0 (en) 2023-09-13
EP2827845B1 (en) 2018-12-26
JP6356660B2 (ja) 2018-07-11

Similar Documents

Publication Publication Date Title
US11759503B2 (en) Compositions of GLP-1 peptides and preparation thereof
ES2965469T3 (es) Composiciones que comprenden un agente de suministro y preparación de estas
US11123296B2 (en) Compositions comprising a delivery agent and preparation thereof
JP5902194B2 (ja) Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物